Trial · NCT01364467
The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
NCT01364467, Phase 2, Completed, Virginia Commonwealth University; results first posted 2020-04-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study. Trials, record NCT01364467. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01364467
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
- NCT number
- NCT01364467
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- Virginia Commonwealth University
- Conditions
- Chronic Rhinitis
- Interventions
- Placebo, Guaifenesin
- First posted
- 2011-06-02
- Last updated
- 2020-04-24
- Results first posted
- 2020-04-24
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Subjective Nasal Scoring | Baseline to 10 Minutes | The Sinus and Nasal Quality of Life Survey (SN-5) questionnaire assesses the impact of infection on nasal symptoms, emotion, and activity. The SN-5 is a 5-item scale with each item rated on a scale of worsening symptoms from 1 (none of the time) through 7 (all of the time). Items were averaged to yield a single score ranging from 1 (better outcomes) to 7 (worse outcomes). Scores were used to asses change in disease severity and the impact of interventions on subjective complaints from baseline to follow-up. |
| Secondary | Nasal Volume | 15 Minutes | Acoustic rhinometry is used to measure cross-sectional volume of the nasal cavity allowing the calculation of nasal volume. |
| Secondary | Nasal Secretion Collection | 10 minutes | To measure the biophysical properties of nasal secretions for improved mucus clearance. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Subjective Nasal Scoring | Baseline to 10 Minutes | score on a scale | MEAN | |
| SECONDARY | Nasal Volume | 15 Minutes | Square centimeters | MEAN | |
| SECONDARY | Nasal Secretion Collection | 10 minutes | Unable to analyze due to insufficient sample material |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Subjective Nasal Scoring | Placebo | 0.62 | Standard Deviation 0.59 | score on a scale | |
| Change in Subjective Nasal Scoring | Guaifenesin | 1.53 | Standard Deviation 1.04 | score on a scale | |
| Nasal Volume | Placebo | Right nostril | 1.10 | Standard Deviation 0.4 | Square centimeters |
| Nasal Volume | Guaifenesin | Right nostril | 1.13 | Standard Deviation 0.66 | Square centimeters |
| Nasal Volume | Placebo | Left nostril | 0.83 | Standard Deviation 0.44 | Square centimeters |
| Nasal Volume | Guaifenesin | Left nostril | 1.08 | Standard Deviation 0.67 | Square centimeters |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 10 | |
| Overall Study | STARTED | Guaifenesin | 20 | |
| Overall Study | COMPLETED | Placebo | 9 | |
| Overall Study | COMPLETED | Guaifenesin | 18 | |
| Overall Study | NOT COMPLETED | Placebo | 1 | |
| Overall Study | NOT COMPLETED | Guaifenesin | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 9 |
| Total, all-cause mortality | Guaifenesin | 0 | 18 |
| Total, other adverse events | Placebo | 0 | 9 |
| Total, other adverse events | Guaifenesin | 0 | 18 |
| Total, serious adverse events | Placebo | 0 | 9 |
| Total, serious adverse events | Guaifenesin | 0 | 18 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Guaifenesin vs Placebo: deaths from any cause | Trial comparisons |
| Guaifenesin vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01364467
GET https://conductscience.org/api/trials/v1/NCT01364467/registered